Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
PharmD, BCIDP Nicholas J Mercuro, MD Christina F Yen, MD, PhD David J Shim, MD; Timothy R Maher, PharmD, BCPS Christopher M Mccoy, BCIDP Peter J Zimetbaum, MD Howard S Gold
JAMA Cardiology, doi:10.1001/jamacardio.2020.1834
Administration of hydroxychloroquine with or without azithromycin for the treatment of coronavirus disease 2019 (COVID-19)-associated pneumonia carries increased risk of corrected QT (QTc) prolongation and cardiac arrhythmias. OBJECTIVE To characterize the risk and degree of QT prolongation in patients with COVID-19 in association with their use of hydroxychloroquine with or without concomitant azithromycin.
DESIGN, SETTING, AND PARTICIPANTS This was a cohort study performed at an academic tertiary care center in Boston, Massachusetts, of patients hospitalized with at least 1 positive COVID-19 nasopharyngeal polymerase chain reaction test result and clinical findings consistent with pneumonia who received at least 1 day of hydroxychloroquine from March 1, 2020, through April 7, 2020.
MAIN OUTCOMES AND MEASURES Change in QT interval after receiving hydroxychloroquine with or without azithromycin; occurrence of other potential adverse drug events. RESULTS Among 90 patients given hydroxychloroquine, 53 received concomitant azithromycin; 44 (48.9%) were female, and the mean (SD) body mass index was 31.5 (6.6). Hypertension (in 48 patients [53.3%]) and diabetes mellitus (in 26 patients [28.9%]) were the most common comorbid conditions. The overall median (interquartile range) baseline QTc was 455 (430-474) milliseconds (hydroxychloroquine, 473 [454-487] milliseconds vs hydroxychloroquine and azithromycin, 442 [427-461] milliseconds; P < .001). Those receiving concomitant azithromycin had a greater median (interquartile range) change in QT interval (23 [10-40] milliseconds) compared with those receiving hydroxychloroquine alone (5.5 [−15.5 to 34.25] milliseconds; P = .03). Seven patients (19%) who received hydroxychloroquine monotherapy developed prolonged QTc of 500 milliseconds or more, and 3 patients (8%) had a change in QTc of 60 milliseconds or more. Of those who received concomitant azithromycin, 11 of 53 (21%) had prolonged QTc of 500 milliseconds or more and 7 of 53 (13 %) had a change in QTc of 60 milliseconds or more. The likelihood of prolonged QTc was greater in those who received concomitant loop diuretics (adjusted odds ratio, 3.38 [95% CI, 1.03-11.08]) or had a baseline QTc of 450 milliseconds or more (adjusted odds ratio, 7.11 [95% CI, 1.75-28.87]). Ten patients had hydroxychloroquine discontinued early because of potential adverse drug events, including intractable nausea, hypoglycemia, and 1 case of torsades de pointes.
CONCLUSIONS AND RELEVANCE In this cohort study, patients who received hydroxychloroquine for the treatment of pneumonia associated with COVID-19 were at high risk of QTc prolongation, and concurrent treatment with azithromycin was associated with greater changes in QTc. Clinicians should carefully weigh risks and benefits if considering hydroxychloroquine and azithromycin, with close monitoring of QTc and concomitant medication usage.
Conflict of Interest Disclosures: None reported.
References
Bhimraj, Morgan, Shumaker, Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 infection, Published
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949Inc, Zithromax, None
Molina, Delaugerre, Goff, No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection,
doi:10.1056/NEJMoa1003833Roden, Harrington, Poppas, Russo, Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus Disease
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:10.1038/s41422-020-0282-0{ 'indexed': {'date-parts': [[2024, 5, 13]], 'date-time': '2024-05-13T18:32:42Z', 'timestamp': 1715625162778},
'reference-count': 15,
'publisher': 'American Medical Association (AMA)',
'issue': '9',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2020, 9, 1]]},
'DOI': '10.1001/jamacardio.2020.1834',
'type': 'journal-article',
'created': {'date-parts': [[2020, 5, 1]], 'date-time': '2020-05-01T15:01:58Z', 'timestamp': 1588345318000},
'page': '1036',
'source': 'Crossref',
'is-referenced-by-count': 498,
'title': 'Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without '
'Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease '
'2019 (COVID-19)',
'prefix': '10.1001',
'volume': '5',
'author': [ { 'given': 'Nicholas J.',
'family': 'Mercuro',
'sequence': 'first',
'affiliation': [ { 'name': 'Department of Pharmacy, Beth Israel Deaconess Medical Center, '
'Boston, Massachusetts'}]},
{ 'given': 'Christina F.',
'family': 'Yen',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Infectious Diseases, Beth Israel Deaconess Medical '
'Center, Harvard Medical School, Boston, Massachusetts'}]},
{ 'given': 'David J.',
'family': 'Shim',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Cardiovascular Medicine, Beth Israel Deaconess '
'Medical Center, Harvard Medical School, Boston, Massachusetts'}]},
{ 'given': 'Timothy R.',
'family': 'Maher',
'sequence': 'additional',
'affiliation': [ { 'name': 'Harvard-Thorndike Electrophysiology Institute, Division of '
'Cardiovascular Medicine, Beth Israel Deaconess Medical, Boston, '
'Massachusetts'}]},
{ 'given': 'Christopher M.',
'family': 'McCoy',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacy, Beth Israel Deaconess Medical Center, '
'Boston, Massachusetts'}]},
{ 'given': 'Peter J.',
'family': 'Zimetbaum',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Cardiovascular Medicine, Beth Israel Deaconess '
'Medical Center, Harvard Medical School, Boston, Massachusetts'},
{ 'name': 'Harvard-Thorndike Electrophysiology Institute, Division of '
'Cardiovascular Medicine, Beth Israel Deaconess Medical, Boston, '
'Massachusetts'}]},
{ 'given': 'Howard S.',
'family': 'Gold',
'sequence': 'additional',
'affiliation': [ { 'name': 'Division of Infectious Diseases, Beth Israel Deaconess Medical '
'Center, Harvard Medical School, Boston, Massachusetts'}]}],
'member': '10',
'reference': [ { 'issue': '0',
'key': 'hbr200007r2',
'first-page': 'E019',
'article-title': '[Expert consensus on chloroquine phosphate for the treatment of novel '
'coronavirus pneumonia].',
'volume': '43',
'author': 'Multicenter Collaboration Group of Department of Science and Technology of '
'Guangdong Province and Health Commission of Guangdong Province for Chloroquine '
'in the Treatment of Novel Coronavirus Pneumonia',
'year': '2020',
'journal-title': 'Zhonghua Jie He He Hu Xi Za Zhi'},
{ 'issue': '3',
'key': 'hbr200007r3',
'doi-asserted-by': 'publisher',
'first-page': '269',
'DOI': '10.1038/s41422-020-0282-0',
'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged '
'novel coronavirus (2019-nCoV) in vitro.',
'volume': '30',
'author': 'Wang',
'year': '2020',
'journal-title': 'Cell Res'},
{ 'key': 'hbr200007r4',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ijantimicag.2020.105949',
'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results '
'of an open-label non-randomized clinical trial.',
'author': 'Gautret',
'year': '2020',
'journal-title': 'Int J Antimicrob Agents'},
{ 'key': 'hbr200007r5',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.medmal.2020.03.006',
'article-title': 'No evidence of rapid antiviral clearance or clinical benefit with the '
'combination of hydroxychloroquine and azithromycin in patients with '
'severe COVID-19 infection.',
'author': 'Molina',
'year': '2020',
'journal-title': 'Med Mal Infect'},
{ 'issue': '20',
'key': 'hbr200007r7',
'doi-asserted-by': 'publisher',
'first-page': '1881',
'DOI': '10.1056/NEJMoa1003833',
'article-title': 'Azithromycin and the risk of cardiovascular death.',
'volume': '366',
'author': 'Ray',
'year': '2012',
'journal-title': 'N Engl J Med'},
{ 'key': 'hbr200007r9',
'article-title': 'Coronavirus disease 2019 (COVID-19) and cardiovascular disease.',
'author': 'Clerkin',
'year': '2020',
'journal-title': 'Circulation'},
{ 'issue': '4',
'key': 'hbr200007r10',
'doi-asserted-by': 'publisher',
'first-page': '479',
'DOI': '10.1161/CIRCOUTCOMES.113.000152',
'article-title': 'Development and validation of a risk score to predict QT interval '
'prolongation in hospitalized patients.',
'volume': '6',
'author': 'Tisdale',
'year': '2013',
'journal-title': 'Circ Cardiovasc Qual Outcomes'},
{ 'issue': '4.23',
'key': 'hbr200007r13',
'article-title': 'Effect of high vs low doses of chloroquine diphosphate as adjunctive '
'therapy for patients hospitalized with severe acute respiratory '
'syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical '
'trial.',
'volume': '3',
'author': 'Borba',
'year': '2020',
'journal-title': 'JAMA Netw Open'},
{ 'key': 'hbr200007r15',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.jacc.2020.04.016',
'article-title': 'Considerations for drug interactions on QTc in exploratory COVID-19 '
'(coronavirus Disease 2019) treatment',
'author': 'Roden',
'year': '2020',
'journal-title': 'J Am Coll Cardiol'},
{ 'key': 'hbr200007r11',
'doi-asserted-by': 'crossref',
'first-page': '3030',
'DOI': '10.1201/9781498747967',
'volume-title': 'Kucers’ The Use of Antibiotics: A Clinical Review of Antibacterial, '
'Antifungal and Antiviral Drugs',
'author': 'Grayson',
'year': '2017',
'edition': '7th ed'},
{ 'key': 'hbr200007r1',
'unstructured': 'US Department of Health & Human Services, Centers for Disease Control '
'and Prevention. Coronavirus (COVID-19). Published 2020. Accessed April '
'10, 2020. https://www.cdc.gov/coronavirus/2019-nCoV/index.html'},
{ 'key': 'hbr200007r6',
'unstructured': 'World Health Organization. The cardiotoxicity of antimalarials: Malaria '
'Policy Advisory Committee Meeting. Published March 24, 2017. Accessed '
'April 21, 2020. '
'https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf'},
{ 'key': 'hbr200007r8',
'doi-asserted-by': 'crossref',
'unstructured': 'Chorin? E, Dai? M, Shulman? E, . The QT interval in patients with '
'SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. '
'Published online April 2, 2020. Accessed April 22, 2020. '
'https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1',
'DOI': '10.1101/2020.04.02.20047050'},
{ 'key': 'hbr200007r12',
'unstructured': 'Pfizer Inc. Zithromax. Published 2019. Accessed April 21, 2020. '
'http://labeling.pfizer.com/ShowLabeling.aspx?id=650'},
{ 'key': 'hbr200007r14',
'doi-asserted-by': 'crossref',
'unstructured': 'Bhimraj? A, Morgan? RL, Shumaker? AH, . Infectious Diseases Society of '
'America guidelines on the treatment and management of patients with '
'COVID-19 infection. Published April 11, 2020. Accessed April 21, 2020. '
'https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/',
'DOI': '10.1093/cid/ciaa478'}],
'container-title': 'JAMA Cardiology',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://jamanetwork.com/journals/jamacardiology/articlepdf/2765631/jamacardiology_mercuro_2020_br_200007_1599683695.70852.pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 10, 22]],
'date-time': '2022-10-22T19:37:46Z',
'timestamp': 1666467466000},
'score': 1,
'resource': {'primary': {'URL': 'https://jamanetwork.com/journals/jamacardiology/fullarticle/2765631'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2020, 9, 1]]},
'references-count': 15,
'journal-issue': {'issue': '9', 'published-print': {'date-parts': [[2020, 9, 1]]}},
'URL': 'http://dx.doi.org/10.1001/jamacardio.2020.1834',
'relation': {},
'ISSN': ['2380-6583'],
'subject': [],
'container-title-short': 'JAMA Cardiol',
'published': {'date-parts': [[2020, 9, 1]]}}
